Article Text

PDF
Ruthenium-106 plaque brachytherapy for symptomatic vasoproliferative tumours of the retina
  1. G Anastassiou1,
  2. N Bornfeld1,
  3. A O Schueler1,
  4. H Schilling1,
  5. S Weber1,
  6. D Fluehs2,
  7. B Jurklies1,
  8. O Vij1,
  9. W Sauerwein2
  1. 1Department of Ophthalmology, University Hospital Essen, 45122 Essen, Germany
  2. 2Department of Radiation Therapy, University Hospital Essen, 45122 Essen, Germany
  1. Correspondence to: Gerasimos Anastassiou MD, Augenklinik, Universitätsklinikum Essen, 45122 Essen, Germany; gerasimos.anastassion{at}uni-essen.de

Abstract

Aim: To investigate the safety and efficacy of β ray brachytherapy in treatment of vasoproliferative tumours of the retina (VTR).

Methods: 35 consecutive patients with symptomatic VTR were treated with a ruthenium-106 (106Ru) plaque. Three tumours had been treated previously (two with cryotherapy; one with transpupillary thermotherapy). 32 VTR (91.4%) were located in the lower half of the retina and all of them were found between the mid-periphery and the ora serrata. The mean tumour thickness was 2.8 mm. An exudative retinal detachment was present in 25 eyes (71.4%) and in 15 cases (42.9%) hard exudates were found in the macula. The major symptom was loss of vision (77.1%).

Results: Brachytherapy was well tolerated by every patient. The mean applied dose was 416 Gy at the sclera and 108 Gy at the tumour apex. In all but four eyes (88.6%), it was possible to control the VTR activity. The median follow up time was 24 months. Three of the above mentioned four eyes with treatment failure had had secondary glaucoma before therapy. There was no case of radiation induced neuropathy or retinopathy. Cataract surgery was necessary for five patients. The development of epiretinal gliosis was the most common event during follow up (n = 10, 28.6%). The mean visual acuity decreased slightly (0.33 before and 0.29 after brachytherapy). Multivariate analysis showed that the presence of macular pathology before treatment was associated with a 6.1-fold risk of vision of 0.25 or better (p = 0.03).

Conclusions: β ray brachytherapy with 1106Ru plaques was able to control the activity of VTR and retain vision. Cases with secondary glaucoma before treatment had a very poor prognosis.

  • PDT, photodynamic therapy
  • RPE, retinal pigment epithelium
  • TTT, transpupillary thermotherapy
  • VTR, vasoproliferative tumours of the retina
  • vasoproliferative tumour
  • retina
  • brachytherapy
  • ocular tumour
  • radiation
  • PDT, photodynamic therapy
  • RPE, retinal pigment epithelium
  • TTT, transpupillary thermotherapy
  • VTR, vasoproliferative tumours of the retina
  • vasoproliferative tumour
  • retina
  • brachytherapy
  • ocular tumour
  • radiation

Statistics from Altmetric.com

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles

    • Editorial
      B Damato